Cargando…
Promise of sodium–glucose co‐transporter‐2 inhibitors in heart failure with mildly reduced ejection fraction
Heart failure with mildly reduced ejection fraction (HFmrEF) is associated with comparable poor outcomes as other subtypes of heart failure and remains a medical unmet need due to the paucity of effective therapies. According to large cardiovascular (CV) outcome trials in patients with heart failure...
Autores principales: | Shen, Xizi, Shen, Xingping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288809/ https://www.ncbi.nlm.nih.gov/pubmed/35642772 http://dx.doi.org/10.1002/ehf2.14005 |
Ejemplares similares
-
Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
por: Wang, Yintang, et al.
Publicado: (2022) -
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
por: Liang, Bo, et al.
Publicado: (2022) -
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022) -
Effects of sodium-glucose cotransporter-2 inhibitors on nutritional status in heart failure with reduced ejection fraction
por: Arslan, Kadem, et al.
Publicado: (2022) -
Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion
por: Hernandez, Michelle, et al.
Publicado: (2022)